Thrombophilia and anticoagulation in pregnancy: Indications, risks and management

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 21, Issue 10, 2008, Pages 685-696

  Montavon, Céline ^a   Hoesli, Irene ^a   Holzgreve, Wolfgang ^a,b   Tsakiris, Dimitrios A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

Anticoagulation; Pregnancy; Pregnancy loss; Thromboembolism; Thrombophilia; Thromboprophylaxis

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; BEMIPARIN; CERTOPARIN; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HEPARIN CALCIUM; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENPROCOUMON; TICLOPIDINE; TINZAPARIN; TIROFIBAN; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MEGADOSE; EMBRYOPATHY; EPIDURAL ANESTHESIA; FETAL HEMORRHAGE; GENE MUTATION; HEART VALVE PROSTHESIS; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOW DRUG DOSE; META ANALYSIS; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOPHILIA; THROMBOSIS PREVENTION; TIME SERIES ANALYSIS; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; HUMANS; MODELS, BIOLOGICAL; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA;

EID: 56549088659     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050802360791     Document Type: Review

References (100)

1. Royal College of Obstetricians and Gynaecologist, editor. Thromboprophylaxis During Pregnancy, Labour and After Vaginal Delivery. Guideline No. 37, London: RCOG Press; 2004.
2. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:844S-886S.
3. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De SV, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001;86:800-803.
4. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-908.
5. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002;101:6-14.
6. Greer IA. Anticoagulants in pregnancy. J Thromb Thrombolysis 2006;21:57-65.
7. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003;90:77-85.
8. Franchini M. Haemostasis and pregnancy. Thromb Haemost 2006;95:401-413.
9. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004;114:409-414.
10. Lockwood CJ. Pregnancy-associated changes in the hemostatic system. Clin Obstet Gynecol 2006;49:836-843.
11. Robertson L, Greer I. Thromboembolism in pregnancy. Curr Opin Obstet Gynecol 2005;17:113-116.
12. Zotz RB, Gerhardt A, Scharf RE. Prediction, prevention, and treatment of venous thromboembolic disease in pregnancy. Semin Thromb Hemost 2003;29:143-154.
13. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171-196.
14. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002;126:1281-1295.
15. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-1231.
16. Haemostasis and thrombosis task force, British committee for standards in haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512-528.
17. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-1532.
18. DeMoerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007;44:106-113.
19. Ohira T, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Zakai NA, Rosamond WD, Folsom AR. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007;5:1455-1461.
20. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163-1174.
21. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000;342:424-425.
22. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367:651-658.
23. Branch W, Eller AG. Antiphospholipid syndrome and thrombosis. Clin Obstet Gynecol 2006;49:861-874.
24. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006;33:2214-2221.
25. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
26. Kaul MS, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007;66:927-930.
27. Wu S, Stephenson MD. Obstetrical antiphospholipid syndrome. Semin Reprod Med 2006;24:40-53.
28. Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost 2007;5 (Suppl 1):276-282.
29. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006;55:360-368.
30. Krabbendam I, Franx A, Bots ML, Fijnheer R, Bruinse HW. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2005;118:143-153.
31. Robertson L, Wu O, Greer I. Thrombophilia and adverse pregnancy outcome. Curr Opin Obstet Gynecol 2004;16:453-458.
32. Brenner B. Thrombophilia and adverse pregnancy outcome. Obstet Gynecol Clin North Am 2006;33:443-456.
33. Stella CL, Sibai BM. Thrombophilia and adverse maternal-perinatal outcome. Clin Obstet Gynecol 2006;49:850-860.
34. Roque H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004;91:290-295.
35. Lissalde-Lavigne G, Cochery-Nouvellon E, Mercier E, Quere I, Dauzat M, Mares P, Gris JC. The association between hereditary thrombophilias and pregnancy loss. Haematologica 2005;90:1223-1230.
36. Makikallio K, Tekay A, Jouppila P. Yolk sac and umbilico-placental hemodynamics during early human embryonic development. Ultrasound Obstet Gynecol 1999;14:175-179.
37. Brenner B. Thrombophilia and pregnancy complications. Pathophysiol Haemost Thromb 2006;35:28-35.
38. Brenner B. Thrombophilia and pregnancy loss in first intended pregnancy. J Thromb Haemost 2005;3:2176-2177.
39. Gris JC, Lissalde-Lavigne G, Quere I, Dauzat M, Mares P. Prophylaxis and treatment of thrombophilia in pregnancy. Curr Opin Hematol 2006;13:376-381.
40. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:141S-159S.
41. Ibbotson T, Perry CM. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002;62:2283-2314.
42. Cheng JW. Fondaparinux: a new antithrombotic agent. Clin Ther 2002;24:1757-1769.
43. Walenga JM, Jeske WP, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005;14:847-858.
44. Ng HJ, Crowther MA. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol 2006;43:S77-S83.
45. Samama MM, Gerotziafas G. New antitoagulants. Ann Pharm Fr 2007;65:85-94.
46. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:160S-198S.
47. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:199S-233S.
48. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet 1976;2:914-915.
49. Schaefer C, Hannemann D, Meister R, Elefant E, Paulus W, Vial T, Reuvers M, Robert-Gnansia E, Arnon J, De SM, et al. Vitamin K antagonists and pregnancy outcome. A multicentre prospective study. Thromb Haemost 2006;95:949-957.
50. Raghav S, Reutens D. Neurological sequelae of intrauterine warfarin exposure. J Clin Neurosci 2007;14:99-103.
51. Pabinger I, Grafenhofer H. Anticoagulation during pregnancy. Semin Thromb Hemost 2003;29:633-638.
52. Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost 2007;97:505-513.
53. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006;61:1432-1440.
54. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006;96:547-552.
55. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:340S-380S.
56. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:381S-453S.
57. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-407.
58. Royal College of Obstetricians and Gynecologists, editor. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. ed. Guideline No. 28, London: RCOG Press; 2007.
59. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia- alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 2002;28:439-446.
60. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005;93:63-69.
61. Bergqvist D. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag 2006;2:365-370.
62. Nijkeuter M, Huisman MV. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Curr Opin Pulm Med 2004;10:338-344.
63. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006;108:1569-1570.
64. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004;350:1914-1915.
65. CLASP. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. Br J Obstet Gynaecol 1995;102:861-868.
66. CLASP. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) collaborative group. Lancet 1994;343:619-629.
67. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:630S-669S.
68. Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007;5:45-55.
69. Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy. Drug News Perspect 2006;19:253-259.
70. Galla JM, Lincoff AM. The role of clopidogrel in the management of ischemic heart disease. Curr Opin Cardiol 2007;22:273-279.
71. Tricoci P, Peterson ED. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. J Interv Cardiol 2006;19:449-455.
72. Hague WM, North RA, Gallus AS, Walters BN, Orlikowski C, Burrows RF, Cincotta RB, Dekker GA, Higgins JR, Lowe SA, et al. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001;175:258-263.
73. Zotz RB, Gerhardt A, Scharf RE. Pregnancy-associated venous thromboembolic disease: prediction, prevention, and therapy. Haemostaseologie 2006;26:63-71.
74. Krivak TC, Zorn KK. Venous thromboembolism in obstetrics and gynecology. Obstet Gynecol 2007;109:761-777.
75. Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, Hamersley SL, Hyers TM, Katz V, Kuhlmann R, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;197:457.e1-21.
76. ACOG. ACOG Practice Bulletin No. 84: prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol 2007;110:429-440.
77. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 3rd ed. - 2005 update. Br J Haematol 2006;132:277-285.
78. Vandermeulen E. Is anticoagulation and central neural blockade a safe combination? Curr Opin Anaesthesiol 1999;12:539-543.
79. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, Mulroy MF, Rosenquist RW, Rowlingson J, Tryba M, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003;28:172-197.
80. Kozek S. Modern anaesthesiological techniques and anticoagulation. Haemostaseologie 2006;26:S41-S51.
81. Parvizi J, Viscusi ER, Frank HG, Sharkey PF, Hozack WJ, Rothman RR. Can epidural anesthesia and warfarin be coadministered? Clin Orthop Relat Res 2006;456:133-137.
82. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191-196.
83. The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-781.
84. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004;191:1024-1029.
85. Carp HJ. Thrombophilia and recurrent pregnancy loss. Obstet Gynecol Clin North Am 2006;33:429-442.
86. Coppens M, Folkeringa N, Teune MJ, Hamulyak K, van der MJ, Prins MH, Buller HR, Middeldorp S. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost 2007;5:1444-1448.
87. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - Yes. J Thromb Haemost 2003;1:2070-2072.
88. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. J Thromb Haemost 2003;1:2073-2074.
89. Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias. Cochrane Database Syst Rev 2003;CD003580.
90. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Mares P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103:3695-3699.
91. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005;3:227-229.
92. Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood 2004;103:4003-4009.
93. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791-1798.
94. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-1057.
95. Petri M, Qazi U. Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2006;32:591-607.
96. Galli M. Improving management of pregnancy in antiphospholipid antibody-positive women. J Rheumatol 2006;33:2108-2109.
97. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;CD002859.
98. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005;83:684-690.
99. Branch DW, Porter TF, Paidas MJ, Belfort MA, Gonik B. Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J Allergy Clin Immunol 2001;108:S133-S138.
100. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006;21:2216-2222.